Dr. Peter Bornstein MD
Partner and Consultant in Infectious Diseases, St. Paul Infectious Disease Associates, Ltd
Member of the Healthcare Council
Council Member Biography
Peter Bornstein, MD, is a Partner and Consultant in Infectious Diseases at St. Paul Infectious Disease Associates, Ltd., in St. Paul, Minnesota. Dr. Bornstein is the Chief of Staff at St. John's Hospital, Maplewood, MN. He spends most of his time seeing critically ill and chronically ill patients. Dr. Bornstein is the Chairman of Infection Control at HealthEast, responsible for oversight of infection control activities. He is an immediate past Chairman of the Antibiotic Subcommittee of the Pharmacy and Therapeutic Committee of a four hospital consortium, HealthEast. Dr. Bornstein formerly served a voluntary position as the Medical Director of Amigos de las Americas, an international non-profit public health and community development agency. Since 1997, he has been named a "Top Doc" in Infectious Diseases in a poll of physicians and nurses for Minneapolis-St. Paul Magazine. Dr. Bornstein is pursuing an MBA at the Carlson School of Management of the University of Minnesota. (This is me - Update Profile)
Employment History
- 1993 - Unspecified
- Partner and Consultant in Infectious Diseases, St. Paul Infectious Disease Associates, Ltd
- 1991 - 1993
- Fellow, Infectious Diseases, Northwestern University Medical School
- 1987 - 1991
- Resident Physician, Henry Ford Hospital
GLG NewsSM Analyses by Peter Bornstein(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
The good news is that these drugs are already approved
October 28, 2009
Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1 | www.medicalnewstoday.com
Adamas has a proprietary mixture of three drugs: amantadine, oseltamivir and ribavirin to treat antiviral resistant strains of novel H1N1 Influenza A.
-
Potential game changer for patients and hospitals regarding C. difficile colitis
July 18, 2009
Rapid DNA Test to Detect Clostridium difficile Infection Approved by FDA Today | www.medscape.com
Clostridium difficile-associated colitis is a disabling, and potentially life-threatening infection. Moreover, hospitals spend great resources in isolating patients with this disease to prevent infection within the hospital. This new technology from Cepheid offers faster, and more accurate diagnosis, leading to potentially quicker treatment for patients, but potentially huge savings for hospitals, that can shorten isolation periods for these patients.
-
18 months too late for this outbreak, but may be the way toward the future.
July 8, 2009
Cadila Pharma-Novavax JV to produce swine flu vaccine | www.business-standard.com
The referenced article states that the joint venture would begin producing swine flu vaccine in two years, possibly based on viral-like particle (VLP) technology. While this is too late to have significant impact in the current pandemic, it points to possible future technologies for vaccine development.
-
April 23, 2009
TB vaccine enters advanced clinical trials at Oxford | timesofindia.indiatimes.com
The decades old BCG vaccine needs to be replaced. It offers at best 50% efficacy, can at times cause severe reaction, and renders subsequent tracking of active TB difficult to impossible. This article describes a trial in South Africa to assess the effectiveness of a new candidate vaccine in infants already immunized with BCG. There is a significant reason why there are so few specifics in the press release.
-
Safety profile similar to placebo! Can't do better than that.
April 6, 2009
Intercell announces European approval of new vaccine, IXIARO®, to prevent Japanese Encephalitis | www.pipelinereview.com
Intercell vaccine is as effective as current JE-VAX, with side-effects similar to placebo. The current JE-VAX is used parsimoniously because of the risk of hypersensitivity reactions. This new vaccine will likely supplant and replace the current vaccine. However, until it has US approval, there may not be recommendations from CDC regarding its use.
Leading institutions connect with Peter Bornstein through GLG
GLG Study Groups with Peter Bornstein(?)
| Study Group Name | No. Members |
|---|---|
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| Infectious Diseases Physicians (US) | 885 |
| Semiconductor Experts in GLG Member Programs (California) | 235 |
| GLG Leaders in the Technology Council | 187 |
GLG Live Meetings with Peter Bornstein(?)
Peter Bornstein has not participated in any GLG Live Meetings.